What is HC Wainwright’s Estimate for HURA Q3 Earnings?

TuHURA Biosciences (NASDAQ:HURA) – Stock analysts at HC Wainwright issued their Q3 2026 earnings estimates for shares of TuHURA Biosciences in a research report issued to clients and investors on Thursday, April 3rd. HC Wainwright analyst R. Burns expects that the company will post earnings per share of ($0.10) for the quarter. HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. HC Wainwright also issued estimates for TuHURA Biosciences’ Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.09) EPS, Q1 2027 earnings at ($0.09) EPS, Q1 2027 earnings at ($0.09) EPS and Q2 2027 earnings at ($0.09) EPS.

HURA has been the subject of a number of other research reports. Rodman & Renshaw started coverage on shares of TuHURA Biosciences in a research note on Thursday, December 19th. They issued a “buy” rating and a $11.00 price target for the company. RODMAN&RENSHAW raised TuHURA Biosciences to a “strong-buy” rating in a research report on Thursday, December 19th.

TuHURA Biosciences Stock Performance

NASDAQ:HURA opened at $3.38 on Friday. TuHURA Biosciences has a one year low of $1.80 and a one year high of $7.93. The stock has a 50-day simple moving average of $3.42.

Institutional Investors Weigh In On TuHURA Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC bought a new position in TuHURA Biosciences during the 4th quarter valued at $1,084,000. Suncoast Equity Management purchased a new stake in shares of TuHURA Biosciences in the fourth quarter worth approximately $421,000. Apollon Wealth Management LLC acquired a new position in TuHURA Biosciences in the 4th quarter worth about $253,000. Northern Trust Corp bought a new position in shares of TuHURA Biosciences during the 4th quarter valued at $234,000. Finally, Squarepoint Ops LLC bought a new position in shares of TuHURA Biosciences in the 4th quarter valued at approximately $223,000. 0.62% of the stock is currently owned by institutional investors.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.